S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• J. A. Zonder,
• J. Richter,
• N. Bumma,
• J. Brayer,
• J. E. Hoffman,
• W. I. Bensinger,
• K. L. Wu,
• L. Xu,
• D. Chokshi,
• A. Boyapati,
• D. Cronier,
• Y. Houvras,
• K. Rodriguez Lorenc,
• G. S. Kroog,
• M. V. Dhodapkar,
• S. Lentzsch,
• D. Cooper,
• S. Jagannath

Affiliations

J. A. Zonder

1 Karmanos Cancer Institute, Detroit

J. Richter

2 Icahn School of Medicine at Mount Sinai, New York

N. Bumma

3 The Ohio State University Comprehensive Cancer Center, Columbus

J. Brayer

4 H. Lee Moffitt Cancer Center, Tampa

J. E. Hoffman

5 University of Miami Health System, Miami

W. I. Bensinger

6 Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, United States of America

K. L. Wu

7 Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium

L. Xu

8 Regeneron Pharmaceuticals, Inc, Tarrytown

D. Chokshi

8 Regeneron Pharmaceuticals, Inc, Tarrytown

A. Boyapati

8 Regeneron Pharmaceuticals, Inc, Tarrytown

D. Cronier

8 Regeneron Pharmaceuticals, Inc, Tarrytown

Y. Houvras

8 Regeneron Pharmaceuticals, Inc, Tarrytown

K. Rodriguez Lorenc

8 Regeneron Pharmaceuticals, Inc, Tarrytown

G. S. Kroog

8 Regeneron Pharmaceuticals, Inc, Tarrytown

M. V. Dhodapkar

9 Emory University School of Medicine, Atlanta

S. Lentzsch

10 Columbia University Medical Center, New York

D. Cooper

11 Rutgers Cancer Institute of New Jersey, New Brunswick, United States of America

S. Jagannath

2 Icahn School of Medicine at Mount Sinai, New York